The made-in-Italy fast-track acceleration program dedicated to projects in life science

ZCube, Research Venture of the pharmaceutical group Zambon, announced the second edition of Open Accelerator, the made-in-Italy fast track acceleration program dedicated to projects in life science fields. Open Accelerator is a 12-steps program providing training to international researchers, scientists and aspiring entrepreneurs that following a selection could receive a seed investment of up to a maximum of 100.000 EUR for each project.

The call for ideas is open until 16 July 2017 and it covers four main areas of interest:

  • Drug delivery systems (systems that allow better drug delivery either through particles or devices);
  • Open source prototyping: medical devices, biomarkers, diagnostics (Instruments and devices that allow safe and effective treatment, rehabilitation, prevention and diagnosis of diseases);
  • Wearables and digital health (technological solutions through wearable devices that improve the cure of diseases; technological platforms or mobile applications that offer new solutions to improve patient's health)
  • Big data (projects related to the data analysis and solutions to improve medical treatment, develop personalized medicine, identify new markers for early diagnosis and that reduce healthcare costs).

"For many years ZCube has been committed to developing partnerships in the field of scientific research through an open approach which aims at establishing relationships with international researchers, centers of excellence and universities around the world," declares Elena Zambon, President of Zambon Spa. "Open Accelerator is an evolution of ZCube created to sustain scientific and digital innovation, the latter being a great agent of change of our times especially in the healthcare sector."

The program is available through the website http://www.openaccelerator.it. A maximum of 30 projects will be selected to participate in the acceleration program that offers training andsupport by mentors and specialized advisors, including entrepreneurs, business angels, venture capitalists and experts from different areas.

The acceleration path is open to researchers and scientists that have the ambition to conduct translational science. The program will be based on the established methodology of the Business Model Canvas that has been adopted by the National Science Foundation (NSF) and the National Institute of Health (NIH) in the United States.

Moreover, ZCube has recently signed a partnership with IAB - Italian Angels for Biotech, the first association of business angels exclusively dedicated to Life Sciences- and Innogest, a leading venture capital fund operating in Italy and in Europe. Advisors from IAB and Innogest, along with other international experts, will participate in the acceleration path providing mentorship and advisory to guide startuppers through the business model creation and and go-to-market strategy development. At the end of the program the most innovative ideas could receive a seed investment of up to Euro 100.000, which will serve as an important catalyst to enter the market.

"Open Accelerator is an arena in which researchers and entrepreneurs are helped to build the foundation of their startups and to prepare for the challenge of reaching out to venture capital that will finance the next stages of their projects," concludes Elena Zambon. "Our accelerator program will become the heart of Open Zone, the scientific campus located near Milan where science oxygenates business. Open Zone is a community of 600 people where new projects, talents and proven expertise come together to help affirming the role of Italy as an ideal country for business innovation."

For further information and to apply, please visit:
http://www.openaccelerator.it

About ZCube Research Venture Zambon Group
For over a decade ZCube has been active in the exploration of innovative technologies with a profile of technology scouting & brokerage at international level. With an experienced team and network of entrepreneurs, business angels and venture capital, ZCube invests in- and supports innovative ideas from early stages of development up to market launch in the fields of drug delivery, medical devices and digital health. ZCube uses a satellite "open source" research model developed by Zambon in order to develop specialized and innovative products in the areas of the company’s therapeutic interest through collaborations with biotech companies, international research centers and universities.

About Open Zone
Open Zone is a scientific campus near Milan with over 7500mq of laboratories and offices 15.550mq, hosting 22 companies operating in the field of biotechnology and Life Sciences. Open Zone is a place where knowledge is shared amongst multiple partners in the life science to foster innovation, synergy and shared development as well as a place aimed at fostering the development of relationships with the community at large. Open Zone is also home to the Museum Zambon and Oxy.gen, a futuristic air-bubble shaped building created from an idea of the Zambon Group and designed by the architect Michele De Lucchi as a place of science associated with breathing.

About Zambon
Zambon is a leading Italian pharmaceutical and fine-chemical multinational company that has earned a strong reputation over the years for high quality products and services. Zambon is well-established in 3 therapeutic areas: respiratory, pain and women’s health, and is very strongly committed to its entry into the CNS space with Xadago® (safinamide) for the treatment of Parkinson’s disease and rare diseases with Promixin® in cystic fibrosis. Zambon is headquartered in Milan and was established in 1906 in Vicenza. Zambon is present in 19 countries with subsidiaries and almost 2,800 employees with manufacturing units in Italy, Switzerland, France, China and Brazil. Zambon products are commercialized in 84 countries.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...

New phase III data shows investigational antibody …

Roche (SIX: RO, ROG; OTCQX: RHHBY) confirmed positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalised patients ...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Prioritizing who gets vaccinated for COVID-19 save…

Waiting for your turn can be frustrating, especially when it comes to COVID-19 vaccinations. But prioritizing who receives the limited supply of vaccines available saves ...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...